Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an autoimmune condition.
In this partnership, Repertoire will deploy its DECODE platform to identify therapeutic targets.
Go deeper with GlobalData
The company will spearhead the target discovery activities, utilising its platform to investigate a vast antigenic space.
Genentech will take the helm for the subsequent preclinical and clinical development, alongside the therapies’ worldwide commercialisation.
Repertoire stands to obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional development, commercial and regulatory milestones, alongside tiered royalties.
Roche corporate business development head Boris Zaïtra said: “As we seek new opportunities to bring an even greater impact to patients, we look forward to translating the new discoveries DECODE and the team at Repertoire will reveal to develop novel medicines for patients suffering from autoimmune diseases.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe platform is at the heart of Repertoire’s approach, designed to map out the immune synapse.
This technology enables an understanding of the interactions between T cell receptors and their corresponding antigenic epitopes.
Founded in 2019 by Flagship Pioneering, Repertoire functions from its bases in the US and Switzerland.
Repertoire Immune Medicines CEO, chairman, and Flagship Pioneering executive partner Torben Straight Nissen said: “Repertoire’s DECODE platform uniquely maps the entire immune synapse in patients and thereby enables development of transformative T cell-targeted medicines for autoimmune diseases and cancer.
“Given Genentech’s commitment and experience as the global market leader in developing treatments for autoimmune diseases, we are delighted to partner with them to bring medicines to patients that reset the immune system and have the potential to provide significant therapeutic benefits.”
The partnership with Genentech follows a previous collaboration in April 2024, where Repertoire joined forces with Bristol Myers Squibb to develop tolerising vaccines aimed at autoimmune conditions.
